keyword
MENU ▼
Read by QxMD icon Read
search

ttfields

keyword
https://www.readbyqxmd.com/read/28425987/biological-activity-of-tumor-treating-fields-in-preclinical-glioma-models
#1
Manuela Silginer, Michael Weller, Roger Stupp, Patrick Roth
Glioblastoma is the most common and aggressive form of intrinsic brain tumor with a very poor prognosis. Thus, novel therapeutic approaches are urgently needed. Tumor-treating fields (TTFields) may represent such a novel treatment option. The aim of this study was to investigate the effects of TTFields on glioma cells, as well as the functional characterization of the underlying mechanisms. Here, we assessed the anti-glioma activity of TTFields in several preclinical models. Applying TTFields resulted in the induction of cell death in a frequency- and intensity-dependent manner in long-term glioma cell lines, as well as glioma-initiating cells...
April 20, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28399638/tumor-treating-fields-plus-chemotherapy-versus-chemotherapy-alone-for-glioblastoma-at-first-recurrence-a-post-hoc-analysis-of-the-ef-14-trial
#2
Santosh Kesari, Zvi Ram
BACKGROUND: This post hoc analysis of the EF-14 trial (NCT00916409) of tumor-treating fields (TTFields) plus temozolomide versus temozolomide alone in newly diagnosed glioblastoma compared the efficacy of TTFields plus chemotherapy (physician's choice) versus chemotherapy alone after first recurrence. METHODS: Patients on TTFields plus temozolomide continued TTFields plus second-line chemotherapy after first recurrence. Some patients on temozolomide alone crossed over after approval of TTFields for recurrent GBM...
April 12, 2017: CNS Oncology
https://www.readbyqxmd.com/read/28358361/tumor-treating-fields-elicit-a-conditional-vulnerability-to-ionizing-radiation-via-the-downregulation-of-brca1-signaling-and-reduced-dna-double-strand-break-repair-capacity-in-non-small-cell-lung-cancer-cell-lines
#3
Narasimha Kumar Karanam, Kalayarasan Srinivasan, Lianghao Ding, Brock Sishc, Debabrata Saha, Michael D Story
The use of tumor-treating fields (TTFields) has revolutionized the treatment of recurrent and newly diagnosed glioblastoma (GBM). TTFields are low-intensity, intermediate frequency, alternating electric fields that are applied to tumor regions and cells using non-invasive arrays. The predominant mechanism by which TTFields are thought to kill tumor cells is the disruption of mitosis. Using five non-small cell lung cancer (NSCLC) cell lines we found that there is a variable response in cell proliferation and cell killing between these NSCLC cell lines that was independent of p53 status...
March 30, 2017: Cell Death & Disease
https://www.readbyqxmd.com/read/28269726/using-computational-phantoms-to-improve-delivery-of-tumor-treating-fields-ttfields-to-patients
#4
Ze'ev Bomzon, Hadas Sara Hershkovich, Noa Urman, Aafia Chaudhry, Dario Garcia-Carracedo, Anders R Korshoej, Uri Weinberg, Cornelia Wenger, Pedro Miranda, Yoram Wasserman, Eilon D Kirson, Yoram
This paper reviews the state-of-the-art in simulation-based studies of Tumor Treating Fields (TTFields) and highlights major aspects of TTFields in which simulation-based studies could affect clinical outcomes. A major challenge is how to simulate multiple scenarios rapidly for TTFields delivery. Overcoming this challenge will enable a better understanding of how TTFields distribution is correlated with disease progression, leading to better transducer array designs and field optimization procedures, ultimately improving patient outcomes...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28269540/simplified-realistic-human-head-model-for-simulating-tumor-treating-fields-ttfields
#5
Cornelia Wenger, Ze'ev Bomzon, Ricardo Salvador, Peter J Basser, Pedro C Miranda
Tumor Treating Fields (TTFields) are alternating electric fields in the intermediate frequency range (100-300 kHz) of low-intensity (1-3 V/cm). TTFields are an anti-mitotic treatment against solid tumors, which are approved for Glioblastoma Multiforme (GBM) patients. These electric fields are induced non-invasively by transducer arrays placed directly on the patient's scalp. Cell culture experiments showed that treatment efficacy is dependent on the induced field intensity. In clinical practice, a software called NovoTalTM uses head measurements to estimate the optimal array placement to maximize the electric field delivery to the tumor...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28269429/investigating-an-alternative-ring-design-of-transducer-arrays-for-tumor-treating-fields-ttfields
#6
Mario Macedo, Cornelia Wenger, Ricardo Salvador, Sofia R Fernandes, Pedro C Miranda
Tumor treating fields (TTFields) is a therapy that inhibits cell proliferation and has been approved by the U.S Food and Drug Administration (FDA) for the treatment of Glioblastoma Multiforme. This anti-mitotic technique works non-invasively and regionally, and is associated with less toxicity and a better quality of life. Currently a device called Optune™ is clinically used which works with two perpendicular and alternating array pairs each consisting of 3×3 transducers. The aim of this study is to investigate a theoretical alternative array design which consists of two rings of 16 transducers and thus permits various field directions...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28268799/first-steps-to-creating-a-platform-for-high-throughput-simulation-of-ttfields
#7
Hadas Sara Hershkovich, Zeev Bomzon, Cornelia Wenger, Noa Urman, Aafia Chaudhry, Dario Garcia-Carracedo, Eilon D Kirson, Uri Weinberg, Yoram Wassermann, Yoram Palti
Tumor Treating Fields (TTFields) are low intensity alternating electric fields in the 100-500 KHz frequency range that are known to have an anti-mitotic effect on cancerous cells. In the USA, TTFields are approved by the Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM) in both the newly diagnosed and recurrent settings. Optimizing treatment with TTFields requires a deep understanding of how TTFields distribute within the brain. To address this issue, simulations using realistic head models have been performed...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28259296/critical-review-of-the-addition-of-tumor-treating-fields-ttfields-to-the-existing-standard-of-care-for-newly-diagnosed-glioblastoma-patients
#8
REVIEW
M Mehta, P Wen, R Nishikawa, D Reardon, K Peters
Since 2005, the standard of care for patients with newly diagnosed glioblastoma (GBM) has consisted of maximal resection followed by radiotherapy plus daily temozolomide (TMZ), followed by maintenance TMZ. In patients selected for clinical trials, median overall survival (OS) and progression-free survival (PFS) with this regimen is 15-17 months and 6-7 months, respectively. There have been various, largely unsuccessful attempts to improve on this standard of care. With the FDA approval of the tumor-treating fields (TTFields) device, Optune, for recurrent GBM (2011), and the more recent EF-14 interim trial results and approval for newly diagnosed GBM patients, several questions have arisen...
March 2017: Critical Reviews in Oncology/hematology
https://www.readbyqxmd.com/read/28227990/using-computational-phantoms-to-improve-delivery-of-tumor-treating-fields-ttfields-to-patients
#9
Ze'ev Bomzon, Hadas Sara Hershkovich, Noa Urman, Aafia Chaudhry, Dario Garcia-Carracedo, Anders R Korshoej, Uri Weinberg, Cornelia Wenger, Pedro Miranda, Yoram Wasserman, Eilon D Kirson, Yoram, Ze'ev Bomzon, Hadas Sara Hershkovich, Noa Urman, Aafia Chaudhry, Dario Garcia-Carracedo, Anders R Korshoej, Uri Weinberg, Cornelia Wenger, Pedro Miranda, Yoram Wasserman, Eilon D Kirson, Yoram, Uri Weinberg, Cornelia Wenger, Noa Urman, Hadas Sara Hershkovich, Yoram Wasserman, Anders R Korshoej, Eilon D Kirson, Dario Garcia-Carracedo, Pedro Miranda, Aafia Chaudhry, Zeev Bomzon, Yoram
This paper reviews the state-of-the-art in simulation-based studies of Tumor Treating Fields (TTFields) and highlights major aspects of TTFields in which simulation-based studies could affect clinical outcomes. A major challenge is how to simulate multiple scenarios rapidly for TTFields delivery. Overcoming this challenge will enable a better understanding of how TTFields distribution is correlated with disease progression, leading to better transducer array designs and field optimization procedures, ultimately improving patient outcomes...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28227795/simplified-realistic-human-head-model-for-simulating-tumor-treating-fields-ttfields
#10
Cornelia Wenger, Ze'ev Bomzon, Ricardo Salvador, Peter J Basser, Pedro C Miranda, Cornelia Wenger, Ze'ev Bomzon, Ricardo Salvador, Peter J Basser, Pedro C Miranda, Peter J Basser, Pedro C Miranda, Cornelia Wenger, Ricardo Salvador, Ze'ev Bomzon
Tumor Treating Fields (TTFields) are alternating electric fields in the intermediate frequency range (100-300 kHz) of low-intensity (1-3 V/cm). TTFields are an anti-mitotic treatment against solid tumors, which are approved for Glioblastoma Multiforme (GBM) patients. These electric fields are induced non-invasively by transducer arrays placed directly on the patient's scalp. Cell culture experiments showed that treatment efficacy is dependent on the induced field intensity. In clinical practice, a software called NovoTal(TM) uses head measurements to estimate the optimal array placement to maximize the electric field delivery to the tumor...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28227675/investigating-an-alternative-ring-design-of-transducer-arrays-for-tumor-treating-fields-ttfields
#11
Mario Macedo, Cornelia Wenger, Ricardo Salvador, Sofia R Fernandes, Pedro C Miranda, Mario Macedo, Cornelia Wenger, Ricardo Salvador, Sofia R Fernandes, Pedro C Miranda, Sofia R Fernandes, Pedro C Miranda, Cornelia Wenger, Ricardo Salvador, Mario Macedo
Tumor treating fields (TTFields) is a therapy that inhibits cell proliferation and has been approved by the U.S Food and Drug Administration (FDA) for the treatment of Glioblastoma Multiforme. This anti-mitotic technique works non-invasively and regionally, and is associated with less toxicity and a better quality of life. Currently a device called Optune™ is clinically used which works with two perpendicular and alternating array pairs each consisting of 3×3 transducers. The aim of this study is to investigate a theoretical alternative array design which consists of two rings of 16 transducers and thus permits various field directions...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/28226993/first-steps-to-creating-a-platform-for-high-throughput-simulation-of-ttfields
#12
Hadas Sara Hershkovich, Zeev Bomzon, Cornelia Wenger, Noa Urman, Aafia Chaudhry, Dario Garcia-Carracedo, Eilon D Kirson, Uri Weinberg, Yoram Wassermann, Yoram Palti, Hadas Sara Hershkovich, Zeev Bomzon, Cornelia Wenger, Noa Urman, Aafia Chaudhry, Dario Garcia-Carracedo, Eilon D Kirson, Uri Weinberg, Yoram Wassermann, Yoram Palti, Yoram Wassermann, Cornelia Wenger, Uri Weinberg, Hadas Sara Hershkovich, Zeev Bomzon, Eilon D Kirson, Dario Garcia-Carracedo, Yoram Palti, Noa Urman, Aafia Chaudhry
Tumor Treating Fields (TTFields) are low intensity alternating electric fields in the 100-500 KHz frequency range that are known to have an anti-mitotic effect on cancerous cells. In the USA, TTFields are approved by the Food and Drug Administration (FDA) for the treatment of glioblastoma (GBM) in both the newly diagnosed and recurrent settings. Optimizing treatment with TTFields requires a deep understanding of how TTFields distribute within the brain. To address this issue, simulations using realistic head models have been performed...
August 2016: Conference Proceedings: Annual International Conference of the IEEE Engineering in Medicine and Biology Society
https://www.readbyqxmd.com/read/27865821/the-effects-of-tumor-treating-fields-and-temozolomide-in-mgmt-expressing-and-non-expressing-patient-derived-glioblastoma-cells
#13
Paul A Clark, Jordan T Gaal, Joslyn K Strebe, Cheri A Pasch, Dustin A Deming, John S Kuo, H Ian Robins
A recent Phase 3 study of newly diagnosed glioblastoma (GBM) demonstrated the addition of tumor treating fields (TTFields) to temozolomide (TMZ) after combined radiation/TMZ significantly increased survival and progression free survival. Preliminary data suggested benefit with both methylated and unmethylated O-6-methylguanine-DNA methyl-transferase (MGMT) promoter status. To date, however, there have been no studies to address the potential interactions of TTFields and TMZ. Thus, the effects of TTFields and TMZ were studied in vitro using patient-derived GBM stem-like cells (GSCs) including MGMT expressing (TMZ resistant: 12...
February 2017: Journal of Clinical Neuroscience: Official Journal of the Neurosurgical Society of Australasia
https://www.readbyqxmd.com/read/27845746/an-overview-of-sub-cellular-mechanisms-involved-in-the-action-of-ttfields
#14
REVIEW
Jack A Tuszynski, Cornelia Wenger, Douglas E Friesen, Jordane Preto
Long-standing research on electric and electromagnetic field interactions with biological cells and their subcellular structures has mainly focused on the low- and high-frequency regimes. Biological effects at intermediate frequencies between 100 and 300 kHz have been recently discovered and applied to cancer cells as a therapeutic modality called Tumor Treating Fields (TTFields). TTFields are clinically applied to disrupt cell division, primarily for the treatment of glioblastoma multiforme (GBM). In this review, we provide an assessment of possible physical interactions between 100 kHz range alternating electric fields and biological cells in general and their nano-scale subcellular structures in particular...
November 12, 2016: International Journal of Environmental Research and Public Health
https://www.readbyqxmd.com/read/27809808/planning-ttfields-treatment-using-the-novotal-system-clinical-case-series-beyond-the-use-of-mri-contrast-enhancement
#15
Jennifer Connelly, Adília Hormigo, Nimish Mohilie, Jethro Hu, Aafia Chaudhry, Nicholas Blondin
BACKGROUND: Gliomas are the most common primary brain tumors in adults and invariably carry a poor prognosis. Recent clinical studies have demonstrated the safety and compelling survival benefit when tumor treating fields (TTFields) are added to temozolomide for patients with newly diagnosed glioblastoma. TTFields are low-intensity, intermediate frequency (200 kHz) alternating electric fields, delivered directly to a patient's brain through the local application of non-invasive transducer arrays...
November 4, 2016: BMC Cancer
https://www.readbyqxmd.com/read/27799506/personalized-treatment-for-a-patient-with-a-braf-v600e-mutation-using-dabrafenib-and-a-tumor-treatment-fields-device-in-a-high-grade-glioma-arising-from-ganglioglioma
#16
Silviya K Meletath, Dean Pavlick, Tim Brennan, Roy Hamilton, Juliann Chmielecki, Julia A Elvin, Norma Palma, Jeffrey S Ross, Vincent A Miller, Philip J Stephens, George Snipes, Veena Rajaram, Siraj M Ali, Isaac Melguizo-Gavilanes
BACKGROUND: Gangliogliomas are slow-growing, low-grade central nervous system tumors affecting children and young adults. However, some patients will experience tumor recurrence and/or malignant progression. This article reports on the clinical history, molecular findings, and treatment response in a patient with BRAF V600-mutated high-grade glioma arising from ganglioglioma. METHODS: Hematoxylin-eosin staining and comprehensive genomic profiling via Foundation One were performed on the tumor sample from a male patient undergoing treatment at the Department of Neuro-Oncology at Baylor University Medical Center...
November 2016: Journal of the National Comprehensive Cancer Network: JNCCN
https://www.readbyqxmd.com/read/27695068/enhancing-predicted-efficacy-of-tumor-treating-fields-therapy-of-glioblastoma-using-targeted-surgical-craniectomy-a-computer-modeling-study
#17
Anders Rosendal Korshoej, Guilherme Bicalho Saturnino, Line Kirkegaard Rasmussen, Gorm von Oettingen, Jens Christian Hedemann Sørensen, Axel Thielscher
OBJECTIVE: The present work proposes a new clinical approach to TTFields therapy of glioblastoma. The approach combines targeted surgical skull removal (craniectomy) with TTFields therapy to enhance the induced electrical field in the underlying tumor tissue. Using computer simulations, we explore the potential of the intervention to improve the clinical efficacy of TTFields therapy of brain cancer. METHODS: We used finite element analysis to calculate the electrical field distribution in realistic head models based on MRI data from two patients: One with left cortical/subcortical glioblastoma and one with deeply seated right thalamic anaplastic astrocytoma...
2016: PloS One
https://www.readbyqxmd.com/read/27675400/personalizing-tumor-treating-fields-ttfields-therapy-with-novotal-implications-for-patterns-of-local-and-distal-recurrence-in-glioblastoma-gb
#18
A Chaudhry, D Garcia-Carracedo, Z Bomzon, H S Hershkovich, C Wenger, U Weinberg, Y Palti
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27674762/computational-simulations-to-determine-optimal-array-layouts-for-delivering-ttfields-to-the-lungs
#19
N Urman, Z Bomzon, H S Hershkovich, U Weinberg, E Kirson, Y Palti
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
https://www.readbyqxmd.com/read/27668388/efficacy-and-safety-of-treating-glioblastoma-with-tumor-treating-fields-therapy
#20
Marlon G Saria, Santosh Kesari
BACKGROUND: Glioblastoma (GBM) is a highly aggressive astrocytoma with a dismal prognosis. Since 1976, only three chemotherapeutic agents have been approved for the treatment of GBM. Tumor-treating fields (TTFields) therapy, delivered via a noninvasive device, is a new therapy approved for use in patients with recurrent GBM and in combination with temozolomide for the treatment of newly diagnosed GBM. OBJECTIVES: This article reviews the mechanism of action and findings from preclinical and clinical studies supporting the use of TTFields for patients with newly diagnosed and recurrent GBM...
October 1, 2016: Clinical Journal of Oncology Nursing
keyword
keyword
110947
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"